Affiliation: University of Massachusetts
- Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?R Rodriguez-Monguio
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts, 322 Arnold House 715 North Pleasant Street, Amherst, MA, 01003 9304, USA
Orphanet J Rare Dis 12:1. 2017....
- Healthcare cost of type 1 diabetes mellitus in new-onset children in a hospital compared to an outpatient settingChristopher F Jasinski
School of Public Health and Health Sciences, University of Massachusetts, Amherst, 715 N Pleasant Street, Amherst, MA 01003, USA
BMC Pediatr 13:55. 2013..e. hemoglobin A1C), healthcare utilization and costs among new-onset type 1 diabetic children who received initial diabetes education and care in a hospital compared to those children in an outpatient pediatric endocrinology clinic...
- Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companiesDiane Nguyen
International Center of Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA
BMC Health Serv Res 13:27. 2013....
- Incentives for orphan drug research and development in the United StatesEnrique Seoane-Vazquez
Division of Pharmacy Practice and Administration, College of Pharmacy, Ohio State University, Columbus, Ohio, USA
Orphanet J Rare Dis 3:33. 2008..This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity life of orphan new molecular entities (NMEs) approved in the US between 1983 and 2007...
- Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacySatish Valluri
College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
BMC Health Serv Res 7:122. 2007..This study compares drug utilization and drug product cost in community vs. mail order pharmacy dispensing services in a Medicaid population...
- Patent life of antiretroviral drugs approved in the US from 1987 to 2007Rosa Rodriguez-Monguio
School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA
AIDS Care 21:760-8. 2009..ARVs had an average of 2-3 more years of effective patent life than other therapeutic classes and, therefore, a longer period without generic competition...